



**Financial aspects of HCV elimination.
Is it „cost saving”?
Cost of screening and treatment.**

Áron Zoltán Vincziczki


Head of Drug reimbursement department
National Health Insurance Fund Hungary

Hungary hepatitis meeting
Budapest, 31- October, 2019



- Existence of HCV was proven only in 1989
- 130-150 million infected patient around the World
- 70-100 thousand carriers of HCV
- Difficult to identify, asymptomatic for decades
- Chronic case: cirrhosis, liver cancer
- With previously infected blood, nowadays mainly among drug users

Authorization process 1.




Priority Index

- **Definition:** Proritization (schedule) of HCV infected patients based on professional aspects (numeric value)
- **Objective components:** stage of liver disease, progression (0-70 point)
- **Special aspects:** eg. HC-workers, already transplanted (10-50 point)
- **Subjective components:** points by physicians, Committee (0-12 point)




Authorization process 2.






Therapeutic possibilities & healing rates





Therapeutic possibilities & healing rates






Therapeutic costs




Cost of 1 SVR 100%=2010





Number of treatments started per year






Waiting list




Waiting list (patient number) for HCV treatment





Results





Hepatitis C treatment: where are we now in Hungary?



2010

- Queue for months
- Long, 48-72 week treatments
- Particularly poor cure rates of 40%
- Approx. 500 healed patients

2018

- Immediate initiation of therapy
- Shortened treatment duration: 8-12 week treatments
- Cure rates approaching 100%
- Approx. 2100 healed patients



Possibilities and challenges for future



- HCV screening programmes (highlighted HC-workers)
- Treatment for IFM failure patient, possibilities to reimburse new therapies
- Exact definition of successful treatment path based on further evaluation and integration to protocol
- Increase the essence of performance basis in other disease groups
- A paradigm shift in access to Hepatitis C drugs: "renaming" the waiting list to the registration list, meaning rapid access to therapy.



**Thank you very much for your
kind attention.**